Thomas Sun

Stanford University — United States

Medicine · Health Sciences

25h-index2.7kcitations70works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(9), Polymer crystallization and properties(8), Lung Cancer Research Studies(7), PI3K/AKT/mTOR signaling in cancer(6), Hair Growth and Disorders(6)

Publications69 total

Virtual Second-Opinion Delivery for Oncology Patients
JCO Oncology Practice·2025
Impact of early palliative care referral in patients with locally advanced and metastatic GI/lung cancer.
JCO Oncology Practice·2024
Shared neutrophil and T cell dysfunction is accompanied by a distinct interferon signature during severe febrile illnesses in children
Nature Communications·2024· 3 citedOpen Access
Scurvy presenting in a homeless 32-year-old male: a case report
European Journal of Clinical Nutrition·2024
Describing Elephants: An Update on the Immunopathology of Multisystem Inflammatory Syndrome in Children
Immunological Investigations·2024Open Access
Immunology of severe febrile illness in children in the COVID-19 era
2023· 1 citedOpen Access
The liquid-liquid equilibrium of polyethylene and ethylene-α-olefin copolymers in 2-methylpentane, n-pentane, and n-hexane: Experimental results and modeling to statistical associating fluid theories
The Journal of Supercritical Fluids·2023· 1 cited
Methanol-Assisted ADMET Polymerization of Semiaromatic Amides
ACS Macro Letters·2023· 1 cited
Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
Molecular-Level Control of Thermal and Morphological Transitions in Semi-Aromatic Polyamides by Cu(I)-Catalyzed Azide–Alkyne Click Polymerization
Macromolecules·2023· 5 cited
Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors
JTO Clinical and Research Reports·2023Open Access
Treatment of Stage IV Non-small Cell Lung Cancer
Respiratory medicine·2023
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites
Endocrine Related Cancer·2022· 9 citedOpen Access
A 24-Year-Old Man Presenting with Lung Metastases from a Primary Retroperitoneal Extragonadal Choriocarcinoma
American Journal of Case Reports·2022· 4 citedOpen Access
CD47 expression patterns in thymic epithelial tumors.
Journal of Clinical Oncology·2022· 1 cited
Correction to “Blends of Polyisoprene with Model Styrene-Olefin Copolymers: Mixing Energetics in Blends versus Block Copolymers”
Macromolecules·2022
Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
Current Oncology Reports·2022· 11 cited
page 1 of 4Next →

Frequent Co-authors

Alessandro Datti(7), Valentina Greco(5), Heather A. Wakelee(5), H. E. King(5), Sukhmani K. Padda(5), David J. Lohse(4), Peggy Myung(4), Frederick S. Vizeacoumar(4), Kathleen Hornbacker(4), Pamela L. Kunz(4), Giovanni Zito(3), Rajesh H. Somani(2), Benjamin S. Hsiao(2), Nikos Hadjichristidis(2), Pamela J. Wright(2), César A. García‐Franco(2), Charles J. Ruff(2), Panteleimon Rompolas(2), Ann M. Haberman(2), Jordan T.F. Young(2)